Molecular biology

New ex-vivo study on low and no calorie sweeteners finds positive impact or no impact on human gut microbiota

Retrieved on: 
Thursday, February 8, 2024
Sorbitol, Psicose, Drink, Potassium, Molecular biology, Microbiota, Food science, Nutrition, Tate & Lyle, Stevia, Diet, Food, Research, Canadian International Council, Erythritol, Soft drink

Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects

Key Points: 
  • Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects
    LONDON, Feb. 8, 2024 /PRNewswire/ - A new, first-of-its-kind study has identified unique and potentially beneficial interactions between certain low and no calorie sweeteners, including stevia, and the human gut microbiota.
  • The doses of low and no calorie sweeteners used were based on actual intakes, regulations and amounts that are generally included in foods and beverages during different timepoints.
  • Assessments of additional low and no calorie sweeteners, including allulose and erythritol, are being completed and details will be shared in due course.
  • The low and no calorie sweeteners studied for this paper included: Acesulfame potassium (aceK), maltitol, sorbitol, stevia, sucralose and tagatose.

Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep

Retrieved on: 
Thursday, February 8, 2024
NGS, Partnership, OEM, Molecular biology, QIAGEN, Acceleration, DNA, Genomics, Fine chemical

Volta Labs and OEM by QIAGEN will partner on the production of reagents and other elements necessary for the development of the Callisto sample preparation kits.

Key Points: 
  • Volta Labs and OEM by QIAGEN will partner on the production of reagents and other elements necessary for the development of the Callisto sample preparation kits.
  • "QIAGEN has paved the way for the acceleration of sample prep and has set the standard for many genomics workflows," said Udayan Umapathi, CEO at Volta Labs.
  • "At OEM by QIAGEN, we are committed to supporting companies like Volta Labs in their mission to revolutionize the field of molecular biology.
  • In supplying reagents for their innovative Callisto Sample Prep System, our partnership aims to elevate NGS technology, addressing the critical bottleneck in NGS sample & library preparation," said Salim Essakali, VP, Head of the OEM Business at QIAGEN.

Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer

Retrieved on: 
Thursday, February 8, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Multimedia, Molecular biology, Growth, Immune system, Gq alpha subunit, Patient, GPCR, Corporation, MBA, Business development, Business, Therapy, Senior advisor, G protein-coupled receptor, CBO, University, Cancer, Management

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.
  • Over the past year, Sean worked with Domain as an independent Senior Advisor, providing strategic input and support to the Company’s management team.
  • This included positions such as Chief Business Officer of iOnctura, Head of Business Development for Cosmo Pharmaceuticals, President and Chief Executive Officer of Corbin Therapeutics Inc, and Vice President of Corporate and Business development at Pharmascience Inc.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “This is an incredible time for Domain Therapeutics, and as the Company continues to grow, I am thrilled to officially welcome Sean to the team.

Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics

Retrieved on: 
Monday, February 5, 2024
Endocrinology, Ageing, Medical school, Nephrology, Health, Genetics, Dean (education), MGH, FAU, Science, Research, Florida Atlantic University, Patient, Fibroblast, HHS, BOCA, Jichi Medical University, Entrepreneurship, University, Harvard Medical School, Therapy, General partnership, Disease, Thiel Fellowship, Former, Biology, MIT, Blueprint, Molecular biology, Conference, Pharmaceutical industry

Kuro-o and Madden will speak at the invite-only Entrepreneurship, Longevity, and Biotech Conference in Boca Raton on February 9 and 10.

Key Points: 
  • Kuro-o and Madden will speak at the invite-only Entrepreneurship, Longevity, and Biotech Conference in Boca Raton on February 9 and 10.
  • The conference assembles biotech and longevity scientists and entrepreneurs to share research and exchange ideas for improving the biotech and longevity industries.
  • He discovered and named the klotho gene in 1997, and since then has written and published extensively on the topic.
  • His pioneering research has opened new and promising paths toward understanding longevity as well as preventing and treating disease.

Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Pharmaceutical, Health, Other Health, DSM-IV codes, Molecular biology, RNA, Obesity, Therapy, Drug development, Diabetes, CMDO, Doctor of Philosophy, University, Development, Pharmacy, Pharmaceutical industry

Resalis Therapeutics today announced the appointment of Almut Nitsche, PhD, as its Chief Medical & Development Officer (CMDO).

Key Points: 
  • Resalis Therapeutics today announced the appointment of Almut Nitsche, PhD, as its Chief Medical & Development Officer (CMDO).
  • In her role at Resalis, she will spearhead the clinical development of RES-010, a non-coding RNA drug candidate designed to address obesity.
  • I look forward to joining the Resalis team as we advance into the Phase 1 trial and seek to establish initial clinical proof of concept for RES-010,” added Almut Nitsche, CMDO of Resalis Therapeutics.
  • Dr. Almut Nitsche is a seasoned expert in pharmaceutical research and development.

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

Retrieved on: 
Wednesday, January 31, 2024
Health, Genetics, Health Technology, Research, Science, Biotechnology, Genomics, Oxford Nanopore Technologies, Growth, DNA, Gene, 3D, University, Database, Weill Cornell Medicine, CSO, Genome-wide association study, Master of Science, Wellcome Sanger Institute, GWAS, Algorithm, Molecular biology, Doctor of Philosophy, Antibiotics

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).
  • Dan’s deep expertise in genomics technology development and commercialisation will be key to achieving the next phase of Enhanc3D Genomics’ growth.
  • Dr Hazel Jones, Chief Operating Officer and interim Chief Executive Officer, Enhanc3D Genomics, said: “Dan joins us at an exciting stage in the Company’s development as we begin to steer towards commercialisation.
  • I look forward to working alongside Dan as he joins the team.”
    Dr Dan Turner, Chief Scientific Officer, Enhanc3D Genomics, commented: “Enhanc3D Genomics has an exceptional reputation in the field of 3D genomics, and I’m delighted to take this opportunity to help drive the development of its technology further.

Checkerspot Announces Breakthrough with the Development of Human Milk Fat Analogue by Fermentation of Microalgae

Retrieved on: 
Tuesday, January 30, 2024
Research, General Health, Consumer, Food, Beverage, Fitness & Nutrition, Parenting, Retail, Science, Baby, Maternity, Biotechnology, Women, Health, Other Science, Multimedia, Infant, Plant, Fat, Parent, Lipid, Milk, Fermentation, Lipid metabolism, Caregiver, Triglyceride, Oil, Carbon, Frontiers, OPO, Rapeseed, Food safety, Microalgae, CSO, Dicarboxylic acid, Molecular biology, Ester, Palmitic acid, Dietary supplement

Checkerspot, a biotechnology company and Certified B Corporation™ that produces unique oils through the fermentation of microalgae, published in Frontiers in Nutrition a breakthrough in the development of a new source of human milk fat analogue known as OPO (Oleic-Palmitic-Oleic or sn-2 palmitate).

Key Points: 
  • Checkerspot, a biotechnology company and Certified B Corporation™ that produces unique oils through the fermentation of microalgae, published in Frontiers in Nutrition a breakthrough in the development of a new source of human milk fat analogue known as OPO (Oleic-Palmitic-Oleic or sn-2 palmitate).
  • Checkerspot is dedicated to advancing the science of viable alternatives by harnessing the potential of its microalgae-based molecular biology and fermentation capabilities.
  • Infant formulas currently available in the market often incorporate structured triglycerides through human milk fat substitutes produced enzymatically.
  • We obtained a unique human milk fat analog containing palmitic acid in sn-2 position in the range of 73% of total palmitic acid.

Beacon Biosignals welcomes David Matthews, PhD, as Chief Business Officer

Retrieved on: 
Thursday, February 1, 2024
Sleep, Intelligence, Molecular biology, Software, Growth, MD, Boston Consulting Group, NIH, Therapy, Neuroscience, Machine learning, Patient, Biological engineering, Biosignal, Disease, Brain, Partner, Medicine, NSF, Medical device, EEG, Doctor of Philosophy, Princeton University, BCG, University, Health

BOSTON, Feb. 1, 2024 /PRNewswire/ -- Beacon Biosignals, a leading computational neurodiagnostics and EEG analytics company, has appointed David Matthews, PhD, as Chief Business Officer to oversee commercial and strategic activities.

Key Points: 
  • Beacon Biosignals partners with top biopharma companies to better understand brain health using clinical-grade EEG and AI-powered analysis.
  • The company's Dreem 3S wearable medical device enables validated sleep endpoints at-home and unlocks a scale of brain activity data never before available.
  • Dr. Matthews will draw on his deep expertise in healthcare strategy, commercial development, and computational neuroscience to create new partnerships, expand relationships, and drive continued innovation for Beacon Biosignals through the company's next phase of growth.
  • "We are thrilled to welcome David to our leadership team," said Jacob Donoghue, MD PhD, CEO of Beacon Biosignals.

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Retrieved on: 
Wednesday, January 24, 2024
Entrepreneurship, Student, Neuroscience, Regeneron Pharmaceuticals, Biochemistry, Materials science, Physics, Research, Environmental science, Mathematics, Animal, Nobel Prize, Social, Knowledge, Chemistry, School, Society, Molecular biology, Medicine, Anxiety, Botany, DSM-IV codes, Creativity, College of Engineering (KNUST), Computational biology, Engineering, Society for Science, Science News, Pharmaceutical industry

TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year’s Regeneron Science Talent Search , the nation’s oldest and most prestigious science and math competition for high school seniors.

Key Points: 
  • TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year’s Regeneron Science Talent Search , the nation’s oldest and most prestigious science and math competition for high school seniors.
  • "We applaud this dynamic group of Regeneron Science Talent Search finalists on their impressive achievement,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • The top 10 Regeneron Science Talent Search 2024 winners will be announced during an awards ceremony on March 12, streamed live from Washington D.C.
  • In total, more than $3 million in awards will be distributed throughout the Regeneron Science Talent Search.

Award-Winning Biotech Training Program to Begin Recruitment with New Employer Partner in Life Sciences

Retrieved on: 
Wednesday, January 17, 2024
Senior, Wistar Institute, Philadelphia Naval Shipyard, Chamber, Navy, BTT, Literacy, PIDC, Commerce, Partnership, Biomedical Research, Biotechnology, Curriculum, Molecular biology, Interview, GED, Shipyard, Navy Yard, Management

This workforce development training will support the talent needs of the rapidly growing cell and gene therapy manufacturing organization.

Key Points: 
  • This workforce development training will support the talent needs of the rapidly growing cell and gene therapy manufacturing organization.
  • "Our partnership with VintaBio marks an exciting era of Life Science development in Philadelphia.
  • “Where other companies at a similar stage may focus on degreed talent, VintaBio is widening its talent pool to include candidates who complete our training program.
  • Hiring local talent is advantageous at every stage of a company life cycle and we applaud VintaBio for recognizing this and taking action."